Hardwick

Researchers are investigating heart failure patients with Non-Ischemic Cardiomyopathy (NICM), a condition where heart failure is not caused by blocked arteries. The study aims to compare survival rates between those who receive an Implantable Cardioverter-Defibrillator (ICD) and those who do not over a period of 36 months, with follow-up extending up to 10 years. This research could influence future international guidelines for managing this type of heart failure. Participants will be randomly assigned to one of two groups: one group will receive an ICD or a Cardiac Resynchronisation Therapy Defibrillator (CRTD), devices implanted under the skin that monitor and correct dangerous heart rhythms. The other group will not receive these devices. The device implantation is done under local anesthesia and includes leads fixed inside the heart chambers. Both groups will be monitored to see if the ICD reduces the risk of death. During the study, participants will undergo assessments including cardiovascular magnetic resonance imaging to evaluate heart scarring. Researchers will monitor survival rates and complications related to device implantation, such as bleeding, infections, or inappropriate shocks. The main outcome measured is the percentage of patients alive at 3 years. Safety and long-term effects will be followed to understand the balance of benefits and risks over time.